摘要
目的观察依折麦布与辛伐他汀不同剂量联合治疗对急性冠脉综合征(ACS)患者炎性指标及尿酸的作用与安全性。方法入选ACS患者81例,随机分为依折麦布与辛伐他汀小剂量联合治疗组(A组)、依折麦布与辛伐他汀常规剂量联合治疗组(B组)及单用辛伐他汀治疗组(C组),进行1周的治疗。比较三组患者治疗前后高敏C反应蛋白(hs-CRP)、白细胞计数(WBC)、中性粒细胞百分比(N)、尿酸(UA)、血脂的变化及患者的不良反应。结果三组患者治疗后hs-CRP、WBC、N及UA水平较治疗前均呈降低趋势,A组与B组治疗前后hs-CRP差异有显著统计学意义(P<0.01)。三组患者治疗前、后低密度脂蛋白-胆固醇(LDL-C)及总胆固醇(TC)水平差异有显著统计学意义(P<0.01)。三组中均无因不良反应退出实验的患者。结论依折麦布与辛伐他汀小剂量联合治疗同常规剂量联合一样能明显抑制ACS的炎性反应,并具有良好的安全性。
Objective To observe the effects and safety of ezetimibe combining simvastatin in different doses on inflammatory indexes and uric acid（UA） in patients with acute coronary syndrome（ACS）.Methods ACS patients（n=81） were randomly divided into group of low-dose ezetimibe combining simvastatin（group A）,group of routine-dose ezetimibe combining simvastatin（group B） and simvastatin group（group C）,and all groups were treated for one week.The changes of high-sensitivity C-reactive protein（hs-CRP）,white blood cell count（WBC）,percentage of neutrophils（N）,UA,blood fat and adverse reactions were compared in three groups before and after the treatment.Results The levels of hs-CRP,WBC,N and UA showed a decreasing trend in three groups after the treatment,and in group A and group B the difference in hs-CRP was statistically significant before and after the treatment（P0.01）.The differences were statistically significant in low-density lipoprotein-cholesterol（LDL-C） and total cholesterol（TC） in three groups before and after the treatment（P0.01）.There were no patients withdrawn due to adverse reactions.Conclusion Ezetimibe combining simvastatin in low dose is as the same as that in routine dose in inhibition of ACS inflammatory reactions and has a higher safety.
出处
《中国循证心血管医学杂志》
2012年第1期43-45,共3页
Chinese Journal of Evidence-Based Cardiovascular Medicine
